One of the most startling revelations of the report is the dramatic delay women face in obtaining accurate diagnoses of bleeding disorders—averaging 14 to 16 years compared to roughly two years for men. This lag significantly exacerbates the health risks associated with these diseases, delaying necessary interventions and increasing morbidity. The report pinpoints heavy menstrual bleeding, impacting up to one-third of women, as a vital but often overlooked early indicator of inherited bleeding disorders, urging clinicians to adopt routine menstrual health assessments to facilitate earlier detection.

The Commission calls for an ambitious yet feasible goal: reducing the average diagnostic delay for women with bleeding disorders to less than 24 months by 2035. Achieving this requires integrating standardized screening protocols into clinical guidelines, bolstering clinician education, and building robust referral networks that prioritize female hematological health. Such systemic changes are essential to overcoming entrenched gender disparities that have long hindered progress.

Beyond delayed diagnosis, the report underscores the underrepresentation of women in clinical trials and the neglect of female-specific hematologic issues in research and policy. This gap has perpetuated a lack of tailored treatment strategies, leaving women vulnerable to adverse outcomes. The Commission advocates for renewed investment in women-centric research, updated clinical guidelines, and enhanced education to address these critical shortfalls.

Postpartum hemorrhage, a leading cause of maternal mortality globally, is another focal point, with the report recommending standardized protocols to improve management and outcomes. In parallel, the authors emphasize the necessity for personalized thrombosis care during pregnancy and the postpartum period, recognizing the unique physiological changes women undergo that influence clotting risks.

Experts hail this report as a pivotal advancement in women’s health and hematology. ISTH President Dr. Pantep Angchaisuksiri highlights its role in uniting clinicians, researchers, and policymakers to address the nuanced challenges women face throughout their lives. The Commission’s evidence-based roadmap provides a transformative call for immediate, coordinated action to deliver equitable, effective hematological care on a global scale.

Dr. Samuelson Bannow concludes with a hopeful vision: “Meaningful progress in bridging these gender gaps is entirely within reach. With focused collaboration across clinical care, research, and education, we can ensure that women and girls everywhere receive the lifesaving hematology care they deserve.” This landmark report offers a powerful blueprint for revolutionizing female blood health and wellbeing worldwide.

Subject of Research: Women’s hematological disorders and health inequities
Article Title: Reducing mortality, improving outcomes, and establishing equity for women with classical haematological disease: a Lancet Haematology Commission
News Publication Date: July 13, 2026
Web References: http://dx.doi.org/10.1016/S2352-3026(26)00079-7
Keywords: Hematology, bleeding disorders, heavy menstrual bleeding, postpartum hemorrhage, thrombosis, women’s health, diagnosis delay, clinical guidelines

Women experience unique hematological challenges due to physiological events such as menstruation, pregnancy, and childbirth, yet these aspects remain woefully underrepresented in clinical studies and health policies. Delayed diagnosis of bleeding disorders is alarmingly common, with women waiting 14 to 16 years on average to receive an accurate diagnosis—vastly longer than the roughly two years observed in men. This diagnostic lag not only perpetuates unnecessary suffering but also diminishes the potential impact of early intervention.

Central to the commission’s findings is the recognition of heavy menstrual bleeding as both a significant health burden and a leading early indicator of inherited bleeding disorders. Affecting up to one-third of women globally, heavy menstrual bleeding is frequently dismissed or inadequately treated, underlining a critical need for systematic menstrual health assessments. The report advocates for widespread adoption of bleeding assessment tools in clinical practice to facilitate earlier detection and referral to specialized care.

The commission sets a bold objective: reducing the average diagnostic delay for female bleeding disorders to under 24 months by 2035. Achieving this requires integrating screening recommendations into major clinical guidelines and equipping healthcare professionals with targeted education on female-specific hematological manifestations. Personalized care models—especially regarding thrombosis management during pregnancy and postpartum—are emphasized as essential for improving maternal outcomes.

Furthermore, the report highlights severe inequities such as higher rates of anemia and complications during pregnancy linked to hematological imbalances, which underscore the urgency of standardized postpartum hemorrhage protocols. The underrepresentation of women in clinical trials emerges as a systemic flaw that hampers the development of effective, evidence-based interventions tailored to female physiology.

Dr. Samuelson Bannow points out that while the existing diagnostic tools and treatments have the capacity to transform women’s hematological health worldwide, real change hinges on coordinated global action involving clinicians, researchers, and policymakers. Enhanced investment in women’s health, coupled with comprehensive prevention programs, could significantly elevate both quality of care and survival outcomes.

ISTH President Dr. Pantep Angchaisuksiri echoes these sentiments, describing the report as a pivotal resource that bridges gaps in knowledge and care delivery. As the conversation around gender-specific medical research gains momentum, this commission provides a scientifically robust roadmap for mitigating disparities and promoting equitable hematology care.

Ultimately, the commission’s work embodies a crucial step toward dismantling gender biases in medicine. Its forward-looking recommendations challenge the medical community to prioritize female hematological health, promising a future where timely diagnosis and personalized treatment become the standard rather than the exception.

Subject of Research: Female hematological conditions, including bleeding disorders and thrombosis
Article Title: Reducing mortality, improving outcomes, and establishing equity for women with classical haematological disease: a Lancet Haematology Commission
News Publication Date: July 13, 2026
Web References: http://dx.doi.org/10.1016/S2352-3026(26)00079-7
Keywords: Hematology, Blood flow, Bleeding, Thrombosis, Menstruation